How will coronavirus hit U.S. drugmakers? Depends what kind of drugmaker you are: Moody's

13th February 2020 Uncategorised 0

There’s no doubt the novel coronavirus outbreak poses a major threat to people’s health. But for U.S. biopharma companies, the fallout isn’t as certain—and some will likely suffer more than others, Moody’s said. Branded drugmakers may see decreased demand while generics players face disrupted supplies.

More: How will coronavirus hit U.S. drugmakers? Depends what kind of drugmaker you are: Moody's
Source: fierce